S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00265785 |
Recruitment Status
:
Terminated
(Closed due to poor accrual)
First Posted
: December 15, 2005
Results First Posted
: November 1, 2012
Last Update Posted
: November 1, 2012
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed disodium may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with stage III or stage IV non-small cell lung cancer.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lung Cancer | Drug: pemetrexed | Phase 2 |
OBJECTIVES:
Primary
- Assess overall survival of patients with selected stage IIIB or IV bronchoalveolar carcinoma treated with pemetrexed disodium.
Secondary
- Evaluate the progression-free survival of patients treated with this drug.
- Evaluate the response rate (confirmed and unconfirmed, partial and complete) in the subset of patients with measurable disease treated with this drug using standard RECIST criteria and computer assisted image analysis.
- Evaluate frequency and severity of toxicities in patients treated with this drug.
- Perform molecular correlative studies on patient tissue to investigate potential predictors of efficacy. (This will not be completed as this study was closed due to poor accrual.)
OUTLINE: Patients are stratified according to prior treatment with gefitinib or erlotinib (yes vs no).
Patients receive pemetrexed disodium intravenous (IV) on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for 3 years.
PROJECTED ACCRUAL: A total of 99 patients will be accrued for this study.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 27 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II Trial of Pemetrexed in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) |
Study Start Date : | July 2006 |
Actual Primary Completion Date : | July 2011 |
Actual Study Completion Date : | July 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: Pemetrexed
pemetrexed
|
Drug: pemetrexed
Pemetrexed 500 mg/m^2 intravenous (IV) over 10 min every 21 days until any of the following criteria is met: (1) Progression of disease or symptomatic deterioration; (2) Unacceptable toxicity; (3) Treatment delay ≥ 3 weeks, for any reason; (4) The patient may withdraw from the study at any time for any reason; (5) Physician's discretion.
Other Name: Alimta
|
- Overall Survival [ Time Frame: 0 - 3 years ]Measured from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.
- Progression-free Survival [ Time Frame: 0 - 3 years ]Progression is defined as any one or more of the following: 20% increase in the sum of longest diameters of target measurable lesions over smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline; Unequivocal progression of non-measurable disease in the opinion of the treating physician (an explanation must be provided); Appearance of any new lesion/site; Death due to disease without prior documentation of progression and without symptomatic deterioration. Symptomatic deterioration is defined as globabl deterioration of health status requiring discontinuation of treatment without objective evidence of progression. Progression-free survival is measured from date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free are censored at date of last contact.
- Response (Confirmed and Unconfirmed, Complete and Partial) [ Time Frame: Assessed at weeks 7 and 13 while on treatment. After off treatment prior to disease progression, disease assessment takes place every 3 months for a maximum of 3 years. ]Complete response (CR) is complete disappearance of all measurable and non-measurable disease. No new lesions. No disease related symptoms. Normalization of markers and other abnormal lab values. Partial Response (PR) is greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Confirmation of CR or PR means a repeat scan at least 4 weeks apart documented before progression or symptomatic deterioration.
- Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug [ Time Frame: Patients were assessed for adverse events 4 weeks after starting treatment. Assessments for adverse events continued after every cycle of treatment (every 3 weeks) for the duration of protocol treatment. ]Adverse Events (AEs) are reported by the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 3.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Histologically confirmed bronchoalveolar carcinoma (BAC) or BAC variants such as adenocarcinoma with BAC features or BAC with invasive adenocarcinoma
- Cytology specimens, such as bronchial brushings, washings, or fine needle aspiration specimens alone are not acceptable for diagnosis
- Stage IV disease OR selected stage IIIB (T4 [secondary to malignant pleural effusion only], any N, M0) disease
- Incompletely resected or unresectable disease
- Pleural effusions, ascites, or laboratory parameters cannot be only evidence of disease
- Measurable disease or nonmeasurable disease documented by CT scan
- No known brain metastases
PATIENT CHARACTERISTICS:
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- SGOT and SGPT ≤ 2.5 times ULN ( ≤ 5 times ULN if due to liver metastases)
- Alkaline phosphatase ≤ 2.5 times ULN ( ≤ 5 times ULN if due to bone metastases)
- Creatinine clearance ≥ 45 mL/min OR creatinine ≤ 1.5 times ULN
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 75,000/mm³
- Zubrod 0-2
- No history of allergic reaction to compounds of similar chemical or biological composition as pemetrexed disodium
- Must provide smoking history
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission
- Not pregnant or nursing
- Fertile patients must use effective contraception
- Able to swallow pills
PRIOR CONCURRENT THERAPY:
- No more than 2 prior systemic therapies (including epidermal growth factor receptor inhibitor)
- At least 28 days since prior systemic therapy
- Patients treated with prior erlotinib or gefitinib must have shown progression since treatment
- No prior pemetrexed disodium
-
At least 28 days since prior radiotherapy and recovered
- Must have measurable or nonmeasurable disease outside previously irradiated area or a new lesion within previously irradiated area
- At least 14 days since prior palliative radiotherapy and recovered
- At least 28 days since prior thoracic or major surgery and recovered
- No concurrent surgery
- No other concurrent therapy (hormonal, biologic or radiotherapy) for this disease
- No concurrent antiretroviral therapy
- Patients should discontinue non-steroidal anti-inflammatory drugs (NSAIDs) with longer half lives (etodolac, ketordac, sulindac, naproxen, naproxen sodium, oxaprozin, nabumetone, diflunisal, salsalate, celecoxib, rofecoxib, valdecoxib, meloxicam, piroxicam) at least 5 days before and for 2 days following pemetrexed treatment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00265785

United States, Alaska | |
Alaska Regional Hospital Cancer Center | |
Anchorage, Alaska, United States, 99508 | |
United States, Arkansas | |
NEA Medical Center - Stadium Boulevard | |
Jonesboro, Arkansas, United States, 72401 | |
United States, California | |
USC/Norris Comprehensive Cancer Center and Hospital | |
Los Angeles, California, United States, 90089-9181 | |
University of California Davis Cancer Center | |
Sacramento, California, United States, 95817 | |
United States, Colorado | |
University of Colorado Cancer Center at UC Health Sciences Center | |
Aurora, Colorado, United States, 80045 | |
Denver Health Medical Center | |
Denver, Colorado, United States, 80204 | |
United States, Hawaii | |
Kapiolani Medical Center at Pali Momi | |
Aiea, Hawaii, United States, 96701 | |
Cancer Research Center of Hawaii | |
Honolulu, Hawaii, United States, 96813 | |
OnCare Hawaii, Incorporated - Lusitana | |
Honolulu, Hawaii, United States, 96813 | |
Queen's Cancer Institute at Queen's Medical Center | |
Honolulu, Hawaii, United States, 96813 | |
Straub Clinic and Hospital, Incorporated | |
Honolulu, Hawaii, United States, 96813 | |
Hawaii Medical Center - East | |
Honolulu, Hawaii, United States, 96817 | |
OnCare Hawaii, Incorporated - Kuakini | |
Honolulu, Hawaii, United States, 96817 | |
Kapiolani Medical Center for Women and Children | |
Honolulu, Hawaii, United States, 96826 | |
Maui Memorial Medical Center | |
Wailuku, Hawaii, United States, 96793 | |
United States, Indiana | |
St. Francis Hospital and Health Centers - Beech Grove Campus | |
Beech Grove, Indiana, United States, 46107 | |
Reid Hospital & Health Care Services | |
Richmond, Indiana, United States, 47374 | |
United States, Kansas | |
Tammy Walker Cancer Center at Salina Regional Health Center | |
Salina, Kansas, United States, 67401 | |
Cotton-O'Neil Cancer Center | |
Topeka, Kansas, United States, 66606 | |
United States, Michigan | |
Saint Joseph Mercy Cancer Center | |
Ann Arbor, Michigan, United States, 48106-0995 | |
CCOP - Michigan Cancer Research Consortium | |
Ann Arbor, Michigan, United States, 48106 | |
Oakwood Cancer Center at Oakwood Hospital and Medical Center | |
Dearborn, Michigan, United States, 48123-2500 | |
Genesys Hurley Cancer Institute | |
Flint, Michigan, United States, 48503 | |
Hurley Medical Center | |
Flint, Michigan, United States, 48503 | |
Van Elslander Cancer Center at St. John Hospital and Medical Center | |
Grosse Pointe Woods, Michigan, United States, 48236 | |
Foote Memorial Hospital | |
Jackson, Michigan, United States, 49201 | |
Sparrow Regional Cancer Center | |
Lansing, Michigan, United States, 48912-1811 | |
St. Mary Mercy Hospital | |
Livonia, Michigan, United States, 48154 | |
St. Joseph Mercy Oakland | |
Pontiac, Michigan, United States, 48341-2985 | |
Mercy Regional Cancer Center at Mercy Hospital | |
Port Huron, Michigan, United States, 48060 | |
Seton Cancer Institute at Saint Mary's - Saginaw | |
Saginaw, Michigan, United States, 48601 | |
Providence Cancer Institute at Providence Hospital - Southfield Campus | |
Southfield, Michigan, United States, 48075 | |
St. John Macomb Hospital | |
Warren, Michigan, United States, 48093 | |
United States, Missouri | |
CCOP - Cancer Research for the Ozarks | |
Springfield, Missouri, United States, 65802 | |
St. John's Regional Health Center | |
Springfield, Missouri, United States, 65804 | |
Hulston Cancer Center at Cox Medical Center South | |
Springfield, Missouri, United States, 65807 | |
United States, Montana | |
CCOP - Montana Cancer Consortium | |
Billings, Montana, United States, 59101 | |
Hematology-Oncology Centers of the Northern Rockies - Billings | |
Billings, Montana, United States, 59101 | |
Northern Rockies Radiation Oncology Center | |
Billings, Montana, United States, 59101 | |
St. Vincent Healthcare Cancer Care Services | |
Billings, Montana, United States, 59101 | |
Billings Clinic - Downtown | |
Billings, Montana, United States, 59107-7000 | |
Bozeman Deaconess Cancer Center | |
Bozeman, Montana, United States, 59715 | |
St. James Healthcare Cancer Care | |
Butte, Montana, United States, 59701 | |
Great Falls Clinic - Main Facility | |
Great Falls, Montana, United States, 59405 | |
Northern Montana Hospital | |
Havre, Montana, United States, 59501 | |
St. Peter's Hospital | |
Helena, Montana, United States, 59601 | |
Glacier Oncology, PLLC | |
Kalispell, Montana, United States, 59901 | |
Kalispell Medical Oncology at KRMC | |
Kalispell, Montana, United States, 59901 | |
Kalispell Regional Medical Center | |
Kalispell, Montana, United States, 59901 | |
Community Medical Center | |
Missoula, Montana, United States, 59801 | |
Guardian Oncology and Center for Wellness | |
Missoula, Montana, United States, 59804 | |
Montana Cancer Specialists at Montana Cancer Center | |
Missoula, Montana, United States, 59807-7877 | |
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center | |
Missoula, Montana, United States, 59807 | |
United States, New York | |
Interlakes Oncology/Hematology PC | |
Rochester, New York, United States, 14623 | |
James P. Wilmot Cancer Center at University of Rochester Medical Center | |
Rochester, New York, United States, 14642 | |
United States, North Carolina | |
Wayne Memorial Hospital, Incorporated | |
Goldsboro, North Carolina, United States, 27534 | |
Rutherford Hospital | |
Rutherfordton, North Carolina, United States, 28139 | |
United States, Ohio | |
Mary Rutan Hospital | |
Bellefontaine, Ohio, United States, 43311 | |
Adena Regional Medical Center | |
Chillicothe, Ohio, United States, 45601 | |
Riverside Methodist Hospital Cancer Care | |
Columbus, Ohio, United States, 43214-3998 | |
CCOP - Columbus | |
Columbus, Ohio, United States, 43215 | |
Grant Medical Center Cancer Care | |
Columbus, Ohio, United States, 43215 | |
Mount Carmel Health - West Hospital | |
Columbus, Ohio, United States, 43222 | |
Doctors Hospital at Ohio Health | |
Columbus, Ohio, United States, 43228 | |
Grandview Hospital | |
Dayton, Ohio, United States, 45405 | |
Good Samaritan Hospital | |
Dayton, Ohio, United States, 45406 | |
Samaritan North Cancer Care Center | |
Dayton, Ohio, United States, 45415 | |
Veterans Affairs Medical Center - Dayton | |
Dayton, Ohio, United States, 45428 | |
CCOP - Dayton | |
Dayton, Ohio, United States, 45429 | |
Grady Memorial Hospital | |
Delaware, Ohio, United States, 43015 | |
Blanchard Valley Medical Associates | |
Findlay, Ohio, United States, 45840 | |
Middletown Regional Hospital | |
Franklin, Ohio, United States, 45005-1066 | |
Charles F. Kettering Memorial Hospital | |
Kettering, Ohio, United States, 45429 | |
Fairfield Medical Center | |
Lancaster, Ohio, United States, 43130 | |
Strecker Cancer Center at Marietta Memorial Hospital | |
Marietta, Ohio, United States, 45750 | |
Licking Memorial Cancer Care Program at Licking Memorial Hospital | |
Newark, Ohio, United States, 43055 | |
Mercy Medical Center | |
Springfield, Ohio, United States, 45504 | |
Community Hospital of Springfield and Clark County | |
Springfield, Ohio, United States, 45505 | |
UVMC Cancer Care Center at Upper Valley Medical Center | |
Troy, Ohio, United States, 45373-1300 | |
Mount Carmel St. Ann's Cancer Center | |
Westerville, Ohio, United States, 43081 | |
Clinton Memorial Hospital | |
Wilmington, Ohio, United States, 45177 | |
Ruth G. McMillan Cancer Center at Greene Memorial Hospital | |
Xenia, Ohio, United States, 45385 | |
Genesis - Good Samaritan Hospital | |
Zanesville, Ohio, United States, 43701 | |
United States, Oregon | |
Legacy Mount Hood Medical Center | |
Gresham, Oregon, United States, 97030 | |
Providence Milwaukie Hospital | |
Milwaukie, Oregon, United States, 97222 | |
Legacy Good Samaritan Hospital & Comprehensive Cancer Center | |
Portland, Oregon, United States, 97210 | |
Providence Cancer Center at Providence Portland Medical Center | |
Portland, Oregon, United States, 97213-2967 | |
Adventist Medical Center | |
Portland, Oregon, United States, 97216 | |
CCOP - Columbia River Oncology Program | |
Portland, Oregon, United States, 97225 | |
Providence St. Vincent Medical Center | |
Portland, Oregon, United States, 97225 | |
Legacy Emanuel Hospital and Health Center and Children's Hospital | |
Portland, Oregon, United States, 97227 | |
Oregon Health and Science University Cancer Institute | |
Portland, Oregon, United States, 97239-3098 | |
Legacy Meridian Park Hospital | |
Tualatin, Oregon, United States, 97062 | |
United States, South Carolina | |
AnMed Cancer Center | |
Anderson, South Carolina, United States, 29621 | |
Roper St. Francis Cancer Center at Roper Hospital | |
Charleston, South Carolina, United States, 29401 | |
CCOP - Greenville | |
Greenville, South Carolina, United States, 29615 | |
CCOP - Upstate Carolina | |
Spartanburg, South Carolina, United States, 29303 | |
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center | |
Spartanburg, South Carolina, United States, 29303 | |
United States, Virginia | |
Danville Regional Medical Center | |
Danville, Virginia, United States, 24541 | |
United States, Washington | |
St. Joseph Cancer Center | |
Bellingham, Washington, United States, 98225 | |
Olympic Hematology and Oncology | |
Bremerton, Washington, United States, 98310 | |
Columbia Basin Hematology | |
Kennewick, Washington, United States, 99336 | |
Fred Hutchinson Cancer Research Center | |
Seattle, Washington, United States, 98104 | |
Harborview Medical Center | |
Seattle, Washington, United States, 98104 | |
Minor and James Medical, PLLC | |
Seattle, Washington, United States, 98104 | |
Group Health Central Hospital | |
Seattle, Washington, United States, 98112 | |
Swedish Cancer Institute at Swedish Medical Center - First Hill Campus | |
Seattle, Washington, United States, 98122-4307 | |
Polyclinic First Hill | |
Seattle, Washington, United States, 98122 | |
University Cancer Center at University of Washington Medical Center | |
Seattle, Washington, United States, 98195-6043 | |
Cancer Care Northwest - Spokane South | |
Spokane, Washington, United States, 99202 | |
Southwest Washington Medical Center Cancer Center | |
Vancouver, Washington, United States, 98668 | |
United States, Wyoming | |
Welch Cancer Center at Sheridan Memorial Hospital | |
Sheridan, Wyoming, United States, 82801 |
Principal Investigator: | Derick H. Lau, MD | University of California, Davis | |
Principal Investigator: | Rachel E. Sanborn, MD | OHSU Knight Cancer Institute |
Responsible Party: | Southwest Oncology Group |
ClinicalTrials.gov Identifier: | NCT00265785 History of Changes |
Other Study ID Numbers: |
CDR0000456424 U10CA032102 ( U.S. NIH Grant/Contract ) S0526 ( Other Identifier: SWOG ) |
First Posted: | December 15, 2005 Key Record Dates |
Results First Posted: | November 1, 2012 |
Last Update Posted: | November 1, 2012 |
Last Verified: | October 2012 |
Keywords provided by Southwest Oncology Group:
bronchoalveolar cell lung cancer stage IIIB non-small cell lung cancer stage IV non-small cell lung cancer recurrent non-small cell lung cancer |
Additional relevant MeSH terms:
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |
Carcinoma, Bronchogenic Bronchial Neoplasms Pemetrexed Antineoplastic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors |